Cargando…

Preclinical study of CC223 as a potential anti-ovarian cancer agent

Aberrant activation of mTOR contributes to ovarian cancer progression. CC223 is a novel and potent mTOR kinase inhibitor. The current study tested its activity against human ovarian cancer cells. We showed that CC223, at nM concentrations, inhibited survival and proliferation of established/primary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Zhenzhen, Niu, Huanfu, Wang, Xuenan, Zhang, Lei, Wang, Qin, Yang, Aijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601667/ https://www.ncbi.nlm.nih.gov/pubmed/28938571 http://dx.doi.org/10.18632/oncotarget.17753

Ejemplares similares

lncRNA UCA1 Mediates Resistance to Cisplatin by Regulating the miR-143/FOSL2-Signaling Pathway in Ovarian Cancer
por: Li, Zewu, et al.
Publicado: (2019)

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022)

Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer
por: Li, Xiaoguang, et al.
Publicado: (2016)

Preclinical Therapeutic Potential of a Nitrosylating Agent in the Treatment of Ovarian Cancer
por: Giri, Shailendra, et al.
Publicado: (2014)

The preclinical analysis of TW-37 as a potential anti-colorectal cancer cell agent
por: Lei, Shun, et al.
Publicado: (2017)

Preclinical study of cinobufagin as a promising anti-colorectal cancer agent
por: Lu, Xing-sheng, et al.
Publicado: (2016)

miRNA-223 is a potential diagnostic and prognostic marker for osteosarcoma
por: Dong, Junbo, et al.
Publicado: (2016)

CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo
por: Xie, Zichen, et al.
Publicado: (2017)

Potential role of miR-9 and miR-223 in recurrent ovarian cancer
por: Laios, Alexandros, et al.
Publicado: (2008)

Preclinical toxicological assessment of a novel monoclonal antibody targeting human platelet-derived growth factor CC (PDGF-CC) in PDGF-CC(hum) mice
por: Zeitelhofer, Manuel, et al.
Publicado: (2018)

The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent
por: Li, Chen, et al.
Publicado: (2015)

Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment
por: McDowell, Anthony, et al.
Publicado: (2021)

CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling
por: Guo, Yangyang, et al.
Publicado: (2020)

Construction and Preclinical Evaluation of (211)At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs
por: Wang, Xudong, et al.
Publicado: (2020)

miR-223 promotes colon cancer by directly targeting p120 catenin
por: Liu, Liwei, et al.
Publicado: (2017)

Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
por: Ladin, Daniel A., et al.
Publicado: (2016)

Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer
por: Lin, Chi-Kang, et al.
Publicado: (2016)

Preclinical activity of melflufen (J1) in ovarian cancer
por: Carlier, Charlotte, et al.
Publicado: (2016)

The Novel Oxazolidinone TBI-223 Is Effective in Three Preclinical Mouse Models of Methicillin-Resistant Staphylococcus aureus Infection
por: Gordon, Oren, et al.
Publicado: (2022)

6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer
por: Shen, He, et al.
Publicado: (2013)

Synthesis and biological evaluation of 3-arylcoumarin derivatives as potential anti-diabetic agents
por: Hu, Yuheng, et al.
Publicado: (2018)

Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2020)

Corrigendum: Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
por: Ladin, Daniel A., et al.
Publicado: (2021)

Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer
por: Zhou, Meng, et al.
Publicado: (2016)

Synthesis and biological evaluation of 3-arylcoumarins as potential anti-Alzheimer's disease agents
por: Yang, Jie, et al.
Publicado: (2019)

SAT-223 Insights into Ovarian Hyperandrogenism: Lessons from Two Unusual Cases
por: Chavez, Luis, et al.
Publicado: (2019)

Harnessing preclinical models for the interrogation of ovarian cancer
por: Qin, Tianyu, et al.
Publicado: (2022)

Imaging and dosimetry for radium-223: the potential for personalized treatment
por: Flux, Glenn D
Publicado: (2017)

Complete chloroplast genomes of the Chlamydomonas reinhardtii nonphotosynthetic mutants CC-1375, CC-373, CC-4199, CC-2359 and CC-1051
por: DeShaw, Alexandra E., et al.
Publicado: (2017)

Synthesis and biological evaluation of 3-arylbenzofuranone derivatives as potential anti-Alzheimer’s disease agents
por: Yang, Jie, et al.
Publicado: (2020)

Advances in the Preclinical Study of Some Flavonoids as Potential Antidepressant Agents
por: German-Ponciano, León Jesús, et al.
Publicado: (2018)

Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids
por: He, Misi, et al.
Publicado: (2016)

The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent
por: Xiong, Zuquan, et al.
Publicado: (2017)

MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression
por: Fang, Gang, et al.
Publicado: (2017)

Role of miR‐223‐3p in pulmonary arterial hypertension via targeting ITGB3 in the ECM pathway
por: Liu, Aijun, et al.
Publicado: (2018)

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
por: Lopez, Salvatore, et al.
Publicado: (2020)

Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent
por: Lv, Huiqing, et al.
Publicado: (2016)

Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours
por: Scotton, C, et al.
Publicado: (2001)

CcRR5 interacts with CcRR14 and CcSnRK2s to regulate the root development in citrus
por: Zhang, Manman, et al.
Publicado: (2023)

An agent-based model of prostate Cancer bone metastasis progression and response to Radium223
por: Casarin, Stefano, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s52s2mlg3upjdsqt7ncu1c9a94